ConductScience.org, home

Paper18686

On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use.

Björkman S and 1 other. Naunyn Schmiedebergs Arch Pharmacol, 1977. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use. Papers, record 18686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/18686

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use.
PubMed
Journal
Naunyn Schmiedebergs Arch Pharmacol
PubMed
Year
1977
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
1.3
iCite
Revised in PubMed
2019-07-25
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Björkman SS
2Sievertsson HH

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MSH Release-Inhibiting HormoneMajor topic
OxotremorineMajor topic
TremorMajor topic
Animals
Dose-Response Relationship, Drug
Male
Mice

Source PubMed

Download CSV of topics

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14633626Deserpidine antagonism by a tripeptide, L-prolyl-L-leucyglycinamide.Neuroendocrinology1973https://conductscience.org/library/papers/4633626PubMed
24212370Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone release-inhibiting factor, thyrotropin releasing hormone and related peptides.FEBS Lett1974https://conductscience.org/library/papers/4212370PubMed
34947365DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF).Life Sci I1971https://conductscience.org/library/papers/4947365PubMed
4238221Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II.Pharmacol Biochem Behav1975https://conductscience.org/library/papers/238221PubMed
55815[Infusion therapy with mif (melanocyte inhibiting factor) in Parkinson's disease (author's transl)].Wien Klin Wochenschr1975https://conductscience.org/library/papers/5815PubMed
64640811Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.Can Med Assoc J1972https://conductscience.org/library/papers/4640811PubMed
73279Double-blind evaluation of oral L-prolyl-Lleucyl-glycine amide in Parkinson's disease.Can Med Assoc J1976https://conductscience.org/library/papers/3279PubMed
85064701Oxotremorine antagonism by a hypothalamic hormone, melanocyte-stimulating hormone release-inhibiting factor (MIF).Proc Soc Exp Biol Med1972https://conductscience.org/library/papers/5064701PubMed
911638Peptides related to melanostatin (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.Acta Pharm Suec1976https://conductscience.org/library/papers/11638PubMed
104614981Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrom.Eur Neurol1974https://conductscience.org/library/papers/4614981PubMed
114746492Dopamine synthesis: stimulation by a hypothalamic factor.Science1973https://conductscience.org/library/papers/4746492PubMed
124858836DOPA potentiation in ablated animals and brain levels of biogenic amines in intact animals after prolyl-leucylglycinamide.Neuroendocrinology1974https://conductscience.org/library/papers/4858836PubMed
137268Commentary: Neuropharmacology of hypothalamic releasing factors.Biochem Pharmacol1976https://conductscience.org/library/papers/7268PubMed
144815Alpha-MSH and MIF-I effects on catecholamine levels and synthesis in various rat brain areas.Pharmacol Biochem Behav1975https://conductscience.org/library/papers/4815PubMed
154837910Oxotremorine antagonism by prolyl-leucyl-glycine-amide administered by different routes and with several anticholinergics.Pharmacol Biochem Behav1974https://conductscience.org/library/papers/4837910PubMed

Download CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
38116429Stapling Amantadine to Melanostatin Neuropeptide: Discovery of Potent Positive Allosteric Modulators of the D2 Receptors.ACS Med Chem Lett2023https://conductscience.org/library/papers/38116429PubMed
33704752Lambda Red-Mediated Recombination in Shiga Toxin-Producing Escherichia coli.Methods Mol Biol2021https://conductscience.org/library/papers/33704752PubMed
207560Behavioural effects of naloxone in rats.Experientia1978https://conductscience.org/library/papers/207560PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
MIF4282PubTator's text mininghttps://conductscience.org/library/genes/4282

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/18686

GET https://conductscience.org/api/papers/v1/18686/authors